Oncotarget最新文献

{"title":"Retraction: Down-regulation of microRNA-320 suppresses cardiomyocyte apoptosis and protects against myocardial ischemia and reperfusion injury by targeting IGF-1.","authors":"Chun-Li Song, Bin Liu, Hong-Ying Diao, Yong-Feng Shi, Ji-Chang Zhang, Yang-Xue Li, Ning Liu, Yun-Peng Yu, Guan Wang, Jin-Peng Wang, Qian Li","doi":"10.18632/oncotarget.28704","DOIUrl":"https://doi.org/10.18632/oncotarget.28704","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"167"},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Signaling pathway dysregulation in breast cancer.","authors":"Dinara Ryspayeva, Attila A Seyhan, William J MacDonald, Connor Purcell, Tyler J Roady, Maryam Ghandali, Nataliia Verovkina, Wafik S El-Deiry, Martin S Taylor, Stephanie L Graff","doi":"10.18632/oncotarget.28701","DOIUrl":"https://doi.org/10.18632/oncotarget.28701","url":null,"abstract":"<p><p>This article provides a comprehensive analysis of the signaling pathways implicated in breast cancer (BC), the most prevalent malignancy among women and a leading cause of cancer-related mortality globally. Special emphasis is placed on the structural dynamics of protein complexes that are integral to the regulation of these signaling cascades. Dysregulation of cellular signaling is a fundamental aspect of BC pathophysiology, with both upstream and downstream signaling cascade activation contributing to cellular process aberrations that not only drive tumor growth, but also contribute to resistance against current treatments. The review explores alterations within these pathways across different BC subtypes and highlights potential therapeutic strategies targeting these pathways. Additionally, the influence of specific mutations on therapeutic decision-making is examined, underscoring their relevance to particular BC subtypes. The article also discusses both approved therapeutic modalities and ongoing clinical trials targeting disrupted signaling pathways. However, further investigation is necessary to fully elucidate the underlying mechanisms and optimize personalized treatment approaches.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"168-201"},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No disease left behind.","authors":"Muzamil Arshad, Connor Lynch, Rohan R Katipally, Sean P Pitroda, Ralph R Weichselbaum","doi":"10.18632/oncotarget.28700","DOIUrl":"https://doi.org/10.18632/oncotarget.28700","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"163-166"},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.","authors":"Wafik S El-Deiry, Catherine Bresson, Fanny Wunder, Benedito A Carneiro, Don S Dizon, Jeremy L Warner, Stephanie L Graff, Christopher G Azzoli, Eric T Wong, Liang Cheng, Sendurai A Mani, Howard P Safran, Casey Williams, Tobias Meissner, Benjamin Solomon, Eitan Rubin, Angel Porgador, Guy Berchem, Pierre Saintigny, Amir Onn, Jair Bar, Raanan Berger, Manon Gantenbein, Zhen Chen, Cristiano de Pádua Souza, Rui Manuel Vieira Reis, Marina Sekacheva, Andrés Cervantes, William L Dahut, Christina M Annunziata, Kerri Gober, Khaled M Musallam, Humaid O Al-Shamsi, Ibrahim Abu-Gheida, Ramon Salazar, Sewanti Limaye, Adel T Aref, Roger R Reddel, Mohammed Ussama Al Homsi, Abdul Rouf, Said Dermime, Jassim Al Suwaidi, Catalin Vlad, Rares Buiga, Amal Al Omari, Hikmat Abdel-Razeq, Luis F Oñate-Ocaña, Finn Cilius Nielsen, Leah Graham, Jens Rueter, Anthony M Joshua, Eugenia Girda, Steven Libutti, Gregory Riedlinger, Mohammed E Salem, Carol J Farhangfar, Ruben A Mesa, Bishoy M Faltas, Olivier Elemento, C S Pramesh, Manju Sengar, Satoru Aoyama, Sadakatsu Ikeda, Ioana Berindan-Neagoe, Himabindu Gaddipati, Mandar Kulkarni, Elisabeth Auzias, Maria Gerogianni, Nicolas Wolikow, Simon Istolainen, Pessie Schlafrig, Naftali Z Frankel, Amanda R Ferraro, Jim Palma, Alejandro Piris Gimenez, Alberto Hernando-Calvo, Enriqueta Felip, Apostolia M Tsimberidou, Roy S Herbst, Josep Tabernero, Richard L Schilsky, Jia Liu, Yves Lussier, Jacques Raynaud, Gerald Batist, Shai Magidi, Razelle Kurzrock","doi":"10.18632/oncotarget.28703","DOIUrl":"https://doi.org/10.18632/oncotarget.28703","url":null,"abstract":"<p><p>The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN's collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"140-162"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143616658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COMETgazing - interesting insights, lessons for clinical practice and a call for more precision using the biomarkerSCOPE.","authors":"Mangesh A Thorat","doi":"10.18632/oncotarget.28698","DOIUrl":"10.18632/oncotarget.28698","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"138-139"},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: MicroRNA-216a inhibits the metastasis of gastric cancer cells by targeting JAK2/STAT3-mediated EMT process.","authors":"Youmao Tao, Songbai Yang, Yuanyu Wu, Xuedong Fang, Yannan Wang, Yan Song, Tao Han","doi":"10.18632/oncotarget.28702","DOIUrl":"10.18632/oncotarget.28702","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"136-137"},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPOSOMES and GENES: The duo influencing CANCER initiation and progression.","authors":"Uzma Saqib, Katherine E Ricks, Alexander G Obukhov, Krishnan Hajela","doi":"10.18632/oncotarget.28696","DOIUrl":"10.18632/oncotarget.28696","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"133-135"},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addendum: Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue.","authors":"Jyoti Roy, Karson S Putt, Domenico Coppola, Marino E Leon, Farah K Khalil, Barbara A Centeno, Noel Clark, Valerie E Stark, David L Morse, Philip S Low","doi":"10.18632/oncotarget.28699","DOIUrl":"10.18632/oncotarget.28699","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"132"},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: FKBP14 overexpression contributes to osteosarcoma carcinogenesis and indicates poor survival outcome.","authors":"Zhongming Huang, Junhua Li, Shaohua Du, Yanghua Tang, Ligang Huang, Luwei Xiao, Peijian Tong","doi":"10.18632/oncotarget.28697","DOIUrl":"10.18632/oncotarget.28697","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"131"},"PeriodicalIF":0.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells.","authors":"Elham Taheri, Maryam Raeeszadeh-Sarmazdeh","doi":"10.18632/oncotarget.28691","DOIUrl":"10.18632/oncotarget.28691","url":null,"abstract":"<p><p>Matrix metalloproteinases (MMPs) are crucial in remodeling the extracellular matrix (ECM), modulating key processes involved in cancer progression, such as migration, invasion, angiogenesis, and metastasis. The overexpression of MMPs, particularly MMP-9, is markedly observed in glioblastoma multiforme (GBM), an aggressive primary brain tumor known for its diffuse and infiltrative nature. Tissue inhibitors of metalloproteinases (TIMPs), endogenous MMP inhibitors, offer significant therapeutic potential due to their wider interaction interfaces relative to small molecule inhibitors. Here, we studied the effect of wild-type human TIMP-1 and TIMP-3 and minimal TIMP variants (mTC1 and mTC3), previously engineered for MMP inhibition, on migration and invasion of GBM cells. Our study focused on minimal TIMP variants, due to their small molecular size and potential in higher cellular uptake and delivery, to assess their potential in cell-based assays. The results demonstrated that the minimal TIMP variants, mTC1, and mTC3, effectively inhibit MMP activity underscoring their potential to limit tumor invasion and progression. Given the lethal nature of GBM and the limited efficacy of current therapies, the application of TIMPs and their engineered minimal variants represents a novel and potentially transformative approach to regulating MMP activity in GBM.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"118-130"},"PeriodicalIF":0.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}